Morgan Stanley upgraded shares of CRH Medical Co. (NYSEAMERICAN:CRHM) from an equal weight rating to an overweight rating in a report published on Friday morning.

CRHM has been the topic of a number of other research reports. Zacks Investment Research lowered CRH Medical from a hold rating to a sell rating in a research note on Tuesday. National Bank Financial raised CRH Medical from a sector perform rating to an outperform rating in a research note on Friday, August 4th. Scotiabank raised CRH Medical from a sector perform rating to a sector outperform rating in a research note on Monday, July 24th. Royal Bank Of Canada raised CRH Medical from a sector perform rating to an outperform rating in a research note on Friday, July 21st. Finally, Canaccord Genuity reduced their price target on CRH Medical from $8.00 to $5.00 and set a buy rating on the stock in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $7.83.

Shares of CRH Medical (NYSEAMERICAN CRHM) traded down $0.05 during trading on Friday, hitting $1.85. The company’s stock had a trading volume of 137,362 shares, compared to its average volume of 129,039. CRH Medical has a one year low of $1.46 and a one year high of $9.25.

COPYRIGHT VIOLATION NOTICE: “CRH Medical Co. (CRHM) Upgraded to Overweight by Morgan Stanley” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/crh-medical-co-crhm-upgraded-to-overweight-by-morgan-stanley/1712456.html.

A number of large investors have recently added to or reduced their stakes in CRHM. Mawer Investment Management Ltd. raised its position in CRH Medical by 25.7% in the third quarter. Mawer Investment Management Ltd. now owns 5,963,519 shares of the company’s stock valued at $15,542,000 after purchasing an additional 1,221,028 shares during the period. Morgan Stanley grew its stake in shares of CRH Medical by 102.7% during the first quarter. Morgan Stanley now owns 1,288,285 shares of the company’s stock valued at $10,564,000 after acquiring an additional 652,737 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in shares of CRH Medical by 513.1% during the third quarter. Canada Pension Plan Investment Board now owns 736,350 shares of the company’s stock valued at $1,914,000 after acquiring an additional 616,239 shares in the last quarter. Pembroke Management LTD grew its stake in shares of CRH Medical by 48.4% during the second quarter. Pembroke Management LTD now owns 1,647,800 shares of the company’s stock valued at $12,160,000 after acquiring an additional 537,200 shares in the last quarter. Finally, Pacific Ridge Capital Partners LLC grew its stake in shares of CRH Medical by 69.7% during the second quarter. Pacific Ridge Capital Partners LLC now owns 1,176,044 shares of the company’s stock valued at $6,703,000 after acquiring an additional 483,070 shares in the last quarter.

About CRH Medical

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Analyst Recommendations for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.